(Q46008262)

18 December 2017

title

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. (English)

1 reference

18 December 2017

diffuse large B-cell lymphoma

1 reference

1 reference

4

1 reference

18 December 2017

Mats Jerkeman

2

object named as

Mats Jerkeman

1 reference

18 December 2017

author name string

Heidi Nyman

1

1 reference

18 December 2017

Marja-Liisa Karjalainen-Lindsberg

3

1 reference

18 December 2017

Sirpa Leppä

5

1 reference

18 December 2017

publication date

15 May 2009

1 reference

18 December 2017

published in

Modern Pathology

1 reference

18 December 2017

volume

22

1 reference

18 December 2017

page(s)

1094-1101

1 reference

18 December 2017

issue

8

1 reference

18 December 2017

https://scigraph.springernature.com/pub.10.1038/modpathol.2009.73

exact match

0 references

cites work

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: a single centre experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

RETRACTED: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

CD10 expression in diffuse large B-cell lymphomas does not influence survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial G

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

inferred from DOI database lookup

7 January 2021

based on heuristic

Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

inferred from DOI database lookup

7 January 2021

based on heuristic

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.73

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/MODPATHOL.2009.73

1 reference

18 December 2017

Dimensions Publication ID

0 references

1 reference

18 December 2017